Asian Pacific Journal of Cancer Prevention

  • 제16권10호
  • /
  • Pages.4317-4321
  • /
  • 2015
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Could the Breast Prognostic Biomarker Status Change During Disease Progression? An Immunohistochemical Comparison between Primary Tumors and Synchronous Nodal Metastasis

  • 발행 : 2015.06.03
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: Prognostic biomarkers in breast cancer are routinely investigated in the primary tumors to guide further management. However, it is proposed that the expression may change during the disease progression, and may result in a different immune profile in the metastatic nodes. This work aimed to investigate the expression of breast prognostic biomarkers in primary tumors and in its axillary nodal metastasis, to estimate the possible discordant expression. Materials and Methods: 60 paired primary and axillary nodal metastasis samples were collected from patients with primary breast cancer with positive nodal deposits, diagnosed at the Maadi Military Hospital, Cairo, Egypt, during the year 2013. ER, PR and HER2 expression was assessed by immunohistochemistry in all samples Results: 48.3% of the included cases showed concordant results for both ER and PR receptors between the primary tumor and its nodal metastasis while 51.7% showed discordant results and the discordance level was statistically significant. On the other hand, 70% of the cases showed concordant Her2 results between the primary tumors and the nodal deposits, 30% showed discordant results and the difference was significant. Conclusions: The study indicated that the discordance in ER and PR receptor expression between the primary breast tumor and their nodal metastasis may be significant. The possible switch in the biomarker status during the disease progression is worth noting and may change the patient therapeutic planning. So, whether the treatment selection should be based on biomarkers in the lymph node is a topic for further studies and future clinical trials.

키워드

참고문헌

  1. Aitken SJ, Thomas JS, Langdon SP, et al (2010). Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases. Ann Oncol, 21, 1254-61. https://doi.org/10.1093/annonc/mdp427
  2. Arapantoni-Dadioti P, Valavanis C, Gavressea T, et al. (2012). Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases. J BUON, 17, 277-83.
  3. Ba JL, Liu CG, Jin F (2014). Alterations in hormonal receptor expression and HER2 status between primary breast tumors and paired nodal metastases: discordance rates and prognosis. Asian Pac J Cancer Prev, 15, 9233-9. https://doi.org/10.7314/APJCP.2014.15.21.9233
  4. Bagaria SP, Ray PS, Sim MS, et al.(2014). Personalizing breast cancer staging by the inclusion of ER, PR, and HER2. JAMA Surg, 149, 125-9. https://doi.org/10.1001/jamasurg.2013.3181
  5. Brouckert O, Paridaens R, Floris G, et al. (2012). A critical review why assessment of steroid hormone receptors in breast cancer should be quantitative. Ann Oncol. 10, 1-7.
  6. Chen W, Yang H, Tang WR, et al. (2014). Updated Meta-analysis on HER2 Polymorphisms and Risk of Breast Cancer: Evidence from 32 Studies. Asian Pac J Cancer Prev, 15, 9643-7. https://doi.org/10.7314/APJCP.2014.15.22.9643
  7. Falck AK, Ferno M, Bendahl PO, et al. (2010). Does analysis of biomarkers in tumor cells in lymph node metastases give additional prognostic information in primary breast cancer?. World J Surg, 34, 1434-41. https://doi.org/10.1007/s00268-010-0499-z
  8. Hoefnagel LD, van de Vijver MJ, van Slooten HJ, et al. (2010). Receptor conversion in distant breast cancer metastases. Breast Cancer Res, 12, 75-7. https://doi.org/10.1186/bcr2645
  9. Huang TH, Wu Fand Loeb GB, et al. (2009). Upregulation of miR-21 by HER2/neu signaling promotes cell invasion. J Biol Chem, 284, 18515-24. https://doi.org/10.1074/jbc.M109.006676
  10. Ibrahim T, Farolfi A, Scarpi E, et al. (2013). Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact. Oncology, 84, 150-7. https://doi.org/10.1159/000345795
  11. Jabbour MN, Massad CY, Boulos FI (2012). Variability in hormone and growth factor receptor expression in primary versus recurrent, metastatic, and post-neoadjuvant breast carcinoma. Breast Cancer Res Treat, 135, 29-37. https://doi.org/10.1007/s10549-012-2047-z
  12. Kinsella MD, Nassar A, Siddiqui MT, et al. (2012). Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and post- neoadjuvant chemotherapy in primary breast carcinoma: a single institutional experience. Int J Clin Exp Pathol, 5, 530-6.
  13. Lindstrom LS, Karlsson E, Wilking UM, et al. (2012). Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol, 20, 2601-8.
  14. Maynadier M, Nirde P, Ramirez JM, et al. (2008). Role of estrogens and their receptors in adhesion and invasiveness of breast cancer cells. Adv Exp Med Biol, 617, 485-491. https://doi.org/10.1007/978-0-387-69080-3_48
  15. Patani N, Martin LA, Dowsett M. (2013). Biomarkers for the clinical management of breast cancer: international perspective. Int J Cancer, 133, 1-13. https://doi.org/10.1002/ijc.27997
  16. Salim DK, Mutlu H, Eryilmaz MK, et al. (2014). Molecular Types and Neoadjuvant Chemotherapy in Patients with Breast Cancer- While Molecular Shifting is More Common in Luminal a Tumors, The Pathologic Complete Response is Most Frequently Observed in Her-2 Like Tumors. Asian Pac J Cancer Prev, 15, 9379-83. https://doi.org/10.7314/APJCP.2014.15.21.9379
  17. Thompson A. M , Jordan L B, Quinlan P, et al. (2010). Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS). Breast Cancer Res, 12, 92-5. https://doi.org/10.1186/bcr2771
  18. Rokutanda N, Horiguchi D, Takata D,et al.(2012). Comparison of hormone receptor and HER2 expression in primary breast cancers and sentinel lymph node metastasis. Cancer Res, 72, 2-5-7. https://doi.org/10.1158/1538-7445.AM2012-2
  19. www.cap.org/aps/docs/committees/.../summary of recommendations.pdf.

피인용 문헌

  1. Screening mammography for second breast cancers in women with history of early-stage breast cancer: factors and causes associated with non-detection vol.19, pp.1, 2019, https://doi.org/10.1186/s12880-018-0303-3